New HER2-detection method assessed in 2D and 3D models
December 2018
University of Rochester Medical Center, Rochester, USA
The study describes the development of a fluorescent nanoparticle-based method to quantify HER2 in breast cancer patient samples and to assess potential treatments. Using monolayer cultures and paraffin-embedded patient biopsies, the researchers compare the efficacy of this new method relative to immunohistochemistry and in situ hybridization. The results show that this method not only improves HER2 quantification, but that this can lead to a better subsetting of breast cancer patients.
A novel detection methodology for HER2 protein quantitation in formalin-fixed, paraffin embedded clinical samples using fluorescent nanoparticles: an analytical and clinical validation study
David G Hicks
Added on: 07-21-2021
[1] https://bmccancer.biomedcentral.com/articles/10.1186/s12885-018-5172-1[2] https://data.jrc.ec.europa.eu/dataset/ffebe454-ed9a-47cf-8a33-8cf70c1b7d38
